Alvotech stock has November 11, 2026 report scheduled

Published on 10/17/2026 at 19:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

2026 revenue guidance is USD 650 million to USD 700 million. Alvotech stock costs EUR 4.45 on October 16, 2026, down 5.84 percent on Nasdaq.

Calendar and company metrics

Alvotech is estimated to report third-quarter results on November 11, 2026.
Full-year 2026 revenue guidance stands at USD 650 million to USD 700 million.
Alvotech stock was last at EUR 4.45 at Lang & Schwarz on October 16, 2026 at 10:58 p.m. CEST, while Nasdaq fell 5.84 percent.
Alvotech had a negative P/E of -7.88 and a market capitalization of USD 1.8 billion on October 16, 2026.

Alvotech, LU2458332611, Illustration mit AI erstellt.

Alvotech is estimated to report its third-quarter 2026 results on November 11, 2026, according to MarketBeat. The date gives investors a defined calendar point after a volatile October for the Nasdaq-listed biosimilar developer.

At Lang & Schwarz, Alvotech was last at EUR 4.45 on October 16, 2026 at 10:58 p.m. CEST. On Nasdaq, the stock closed at USD 5.00 on October 16, 2026, down 5.84 percent versus the prior close of October 15, 2026.

Revenue guidance for 2026

Alvotech expects full-year 2026 revenue of USD 650 million to USD 700 million, a range reported by Simply Wall St. The range frames the November reporting date around sales execution rather than a single point estimate.

Price position on Nasdaq

The Nasdaq quote placed Alvotech at USD 5.00 against a 52-week range of USD 2.94 to USD 8.74 on October 16, 2026. The stock was 42.79 percent below its 52-week high and 70.07 percent above its 52-week low. Trading volume was 1,058,953 shares, versus an average volume of 1,097,365 shares.

Valuation and reporting date

Alvotech had a market capitalization of USD 1.8 billion and a negative trailing P/E of -7.88 on October 16, 2026. The November 11 reporting date is the next scheduled corporate milestone cited by MarketBeat, with the conference call set for November 12, 2026.

Comparison with peers

Alvotech (Nasdaq, USD): minus 5.84 percent, P/E -7.88, market capitalization USD 1.8 billion

Sanofi (Nasdaq, USD): plus 0.79 percent, P/E 22.20, market capitalization USD 97.3 billion

Teva Pharmaceutical Industries (NYSE, USD): plus 0.95 percent, P/E 68.97, market capitalization USD 48.4 billion

The dated price picture

Alvotech's October 16, 2026 Nasdaq decline contrasted with gains for both comparison companies. The upcoming results date and the 2026 revenue range provide the clearest scheduled reference points for the stock's next major assessment.

The further course of trading is shown by the continuously updated real-time quote of Alvotech stock.